Abstract

Aim: Cancer, one of the diseases with the highest mortality rates worldwide, is treated using various methods. Among these methods, the use of agents exhibiting antioxidant activity has increased significantly. Ramelteon, a melatonin receptor agonist, is an agent that stands out for its antioxidant and anti-inflammatory properties. The aim of this study is to reveal the cytotoxic and genotoxic effects of Ramelteon on different types of human cancer cells.
Materials and Methods: In the study, Ramelteon was applied at concentrations of 5, 10, 25, 50, 100, and 500 µM to human ovarian (A2780), breast (MCF-7), colon (Caco-2), and prostate (LNCaP) cancer cell lines and incubated for 24 hours. Changes in cell viability were determined using the MTT assay method. After determining the dose-dependent effect, the inhibitory concentration 50 calculations were performed. The genotoxic effect was examined using the Comet Assay method according to the determined effective dose. Intergroup comparisons were performed using the Kruskal Wallis H test. When statistically significant differences were found between groups, multiple comparisons were performed using the Bonferroni-corrected Mann Whitney U test (p

Key words: Colon Cancer; Melatonin; Breast Cancer; Prostate Cancer; Ramelteon; Ovarian Cancer